LuPSMA moves UpFront | first RCT data with Arun Azad and Michael Hofman

A big day at ESMO in Barcelona today as our friend and colleague A/Professor Arun Azad presents the results of the UpFront PSMA trial for the first time. The data were revealed in the main prostate cancer session at ESMO and simultaneously published in Lancet Oncology. UpFront PSMA is a randomised controlled trial comparing ADT and docetaxel, with ADT + done + LuPSMA in men newly diagnosed high-volume mHSPC. This is a world-first readout of LuPSMA in a prospective randomised trial for mHSPC, and clearly shows a benefit.

We dive into the details today with Arun, and another friend and colleague, Professor Michael Hofman, nuc med lead for UpFront PSMA. Also available as an audio podcast in all the usual places, just search GU Cast.

This is a Themed Podcast supported by our Silver Partners, Novartis.

Check out the full paper in Lancet Oncology https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00440-6/fulltext

Also available as an audio podcast, just search GU Cast wherever you get yours. Or play directly below